Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Menarini Expands In Cancer With Radius Drug Deal

Elacestrant Is An Oral SERD In Phase III For Breast Cancer

Executive Summary

Although Elonzris, the therapy at the heart of its recent acquisition of Stemline has just been rejected in Europe, Italy's Menarini is pushing on with its expansion in oncology and is paying $30m upfront to get the rights to Radius Health's Phase III hope elacestrant.

You may also be interested in...



Radius Business Review Ends In Sale To Investment Funds

Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.

Menarini And Radius Skip Into SERD Lead With Elacestrant Success

Elacestrant has become the first oral SERD to generate positive topline results in a pivotal study as a monotherapy versus standard of care for ER+/HER2- advanced or metastatic breast cancer.

Finance Watch: DRI Healthcare’s Canadian IPO Enables More Royalty Deals

Public Company Edition: US initial public offerings are reawakening from a brief nap as Prometheus and Longboard prepare IPOs for launch. Also, Halozyme sells $700m worth of notes and Karuna’s $250m stock sale leads recent follow-on offerings.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel